Research Article| Volume 42, ISSUE 12, P1780-1788, August 2006

CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: A randomised trial (GABG trial IV-A-93)


      Gonadotrophin-releasing hormone analogues were investigated as adjuvant treatment for patients with node-negative, hormone-sensitive, premenopausal breast cancer. Patients were randomised to either three cycles of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) chemotherapy (n = 378) or goserelin every 28 d for 2 years (n = 393). During a median follow-up of 4.9 years, 123 events were observed. The first-failure event of CMF versus goserelin, respectively, was ipsilateral locoregional recurrence (18 versus 20), contralateral breast cancer (7 versus 6), distant failure (35 versus 24) and death without recurrence (2 versus 2). Forty-two (23 versus 19) deaths of any cause occurred. The estimated adjusted hazard ratio for goserelin versus CMF (intention-to-treat analysis) was 0.79 (95% CI = 0.54–1.14; P = 0.19). It is concluded that medical ovarian ablation with goserelin represents a valid option for premenopausal patients with node-negative breast cancer.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Beatson G.T.
        On the treatment of inoperable carcinoma of the mamma: suggestions for a new method of treatment, with illustrative cases.
        Lancet. 1898; 2: 104-162
      1. Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687–717.

        • Dees E.C.
        • Davidson N.E.
        Ovarian ablation as adjuvant therapy for breast cancer.
        Semin Oncol. 2001; 28: 322-331
        • Goldhirsch A.
        • Wood W.C.
        • Gelber R.D.
        • et al.
        Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer.
        J Clin Oncol. 2003; 21: 3357-3365
        • Maass H.H.
        3 versus 6 cycles of CMF in breast cancer patients with 1 to 9 positive nodes: results of the German Adjuvant Breast Cancer Group (GABG) III Trial.
        Proc ASCO. 2000; 19: 283
        • Schumacher M.
        • Bastert G.
        • Bojar H.
        • et al.
        Randomized 2 x 2 trial evaluating hormonal treatment and the duration of chemotherapy in node-positive breast cancer patients. German Breast Cancer Study Group.
        J Clin Oncol. 1994; 12: 2086-2093
      2. International Breast Cancer Study Group. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients. J Clin Oncol 1996;14:1885–1894.

        • Colleoni M.
        • Litman H.J.
        • Castiglione-Gertsch M.
        • et al.
        Duration of adjuvant chemotherapy for breast cancer: a joint analysis of two randomised trials investigating three versus six courses of CMF.
        Br J Cancer. 2002; 86: 1705-1714
        • Jonat W.
        • Kaufmann M.
        • Sauerbrei W.
        • et al.
        Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study.
        J Clin Oncol. 2002; 20: 4628-4635
        • Kaufmann M.
        • Jonat W.
        • Blamey R.
        • et al.
        Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
        Eur J Cancer. 2003; 39: 1711-1717
        • von Minckwitz G.
        • von der Assen A.
        • Blohmer J.U.
        • et al.
        Medical ovarian ablation (Goserelin 2 yrs.) versus polychemotherapy (CMF x 3) in premenopausal patients with node-negative, receptor positive breast cancer – GABG trial ‘IV-A-93’.
        The Breast. 2001; 10 (abstr): S28
        • von Minckwitz G.
        • Graf E.
        • Geberth M.
        • et al.
        Goserelin versus CMF as adjuvant therapy for node-negative, hormone receptor-positive breast cancer in premenopausal patients. The GABG IV-A-93 Trial.
        Proc ASCO. 2004; 23 (abstr): 534
        • Remmele W.
        • Stegner H.E.
        Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue.
        Pathologe. 1987; 8: 138-140
        • Schmoor C.
        • Olschewski M.
        • Sauerbrei W.
        • et al.
        Long-term follow-up of patients in four prospective studies of the German Breast Cancer Study Group (GBSG): a summary of key results.
        Onkologie. 2002; 25: 143-150
        • Schoenfeld D.A.
        Sample-size formula for the proportional-hazards regression model.
        Biometrics. 1983; 39: 499-503
        • Schemper M.
        • Smith T.L.
        A note on quantifying follow-up in studies of failure time.
        Cont Clin Trials. 1996; 17: 343-346
        • Clark T.G.
        • Altman D.G.
        • De Stavola B.L.
        Quantification of the completeness of follow-up.
        Lancet. 2002; 359: 1309-1310
        • Kalbfleisch J.D.
        • Prentice R.L.
        The statistical analysis of failure time data.
        Wiley, New York1980
        • Rutgers E.J.
        EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer.
        Eur J Cancer. 2001; 37: 447-453
        • Kaufmann M.
        • Graf E.
        • Jonat W.
        • et al.
        Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93).
        J Clin Oncol. 2005; 23: 7842-7848
        • Kaufmann M.
        • Graf E.
        • Jonat W.
        • et al.
        Goserelin versus control after adjuvant, riskadapted chemotherapy in premenopausal patients with breast cancer: GABG-IV B-93.
        J Clin Oncol. 2004; 22 (abstr): 588
        • Eiermann W.
        • Graf E.
        • Raab G.
        • et al.
        Highdose epirubicin vs. standard-dose epirubicin cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: First results of a randomised trial of the German Adjuvant Breast Cancer Group (GABG).
        Proc Am Soc Clin Oncol. 2001; 20 (abstr 127): A-127
        • Kaufmann M.
        • Jonat W.
        • Blamey R.
        • et al.
        Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
        Eur J Cancer. 2003; 39: 1711-1717
        • Castiglione-Gertsch M.
        • O’Neill A.
        • Price K.N.
        • et al.
        Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomised trial.
        J Natl Cancer Inst. 2003; 95: 1833-1846
        • Engelsman E.
        • Klijn J.C.
        • Rubens R.D.
        • et al.
        ‘Classical’ CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808).
        Eur J Cancer. 1991; 27: 966-970
        • Jakesz R.
        • Hausmanninger
        • Kubista E.
        • et al.
        Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer – Austrian Breast and Colorectal Cancer Study Group Trial 5.
        J Clin Oncol. 2002; 20: 4621-4627